search
Back to results

CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism

Primary Purpose

Venous Thromboembolic Disease, Pulmonary Embolism, Venous Thromboembolism

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
The multifaceted interventions
Routine VTE prophylaxis
Sponsored by
China-Japan Friendship Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Venous Thromboembolic Disease focused on measuring Quality improvement, Venous Thromboembolism, Hospital Associated-VTE

Eligibility Criteria

14 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Aged ≥14 years
  2. Have an expected hospital stay ≥72 hours for medical and/or surgical treatment
  3. Written informed consent

Exclusion Criteria:

  1. Inability to be followed-up at until 3 months after randomization
  2. Have participated in similar trials or are undergoing other clinical trials
  3. Refuse or are unable to give informed consent
  4. VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment
  5. Requiring a full dose of anticoagulant treatment (e.g., recent VTE, atrial fibrillation).

Sites / Locations

  • China-Japan Friendship HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

The multifaceted QI interventions

Routine VTE prophylaxis in local clinical practice

Arm Description

Hospitals randomized into experimental group will implement follow interventions including:the distribution of the guideline and pathway, a computer alert(computer-based clinical decision support system and computerized reminders),audit and feedback.

Patients in the routine VTE prophylaxis(control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices.

Outcomes

Primary Outcome Measures

Proportion of appropriate prophylaxis rate during hospitalization
The proportion of appropriate prophylaxis is defined as the number of appropriate prophylaxis among the patients at risk of VTE and without corresponding contraindications.
The proportion of participants who developed the VTE(all, symptomatic, asymptomatic VTE)
The incidence of HA-VTE is defined as the proportion of participants who developed the VTE(all, symptomatic, asymptomatic VTE)

Secondary Outcome Measures

All-cause mortality
Proportion of participants who was dead(all-cause mortality)
Proportion of complications related to the intervention
complications(i.e. major bleeding,minor bleeding, thrombocytopenia) related to the intervention

Full Information

First Posted
December 8, 2019
Last Updated
January 19, 2023
Sponsor
China-Japan Friendship Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04211181
Brief Title
CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism
Official Title
Effect on Thromboprophylaxis Among Hospitalized Patients Using a System-wide Multifaceted Quality Improvement Intervention: Rationale and Design for a Multicenter Cluster Randomized Clinical Trial in China
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2022 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
China-Japan Friendship Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Although pharmacologic and mechanical methods to prevent VTE are safe, effective, cost-effective, and advocated by authoritative guidelines,many studies continue to demonstrate that these preventive methods are significantly underutilized, especially in China.A number of quality improvements (QI) program have been established in several countries or hospitals.However,no exit effective protocol has been demonstrated well enough or adequate to drive breakthrough levels of improvement. A reliable and practical QI that can support hospitals or physicians in China is warranted.To evaluate the multifaceted quality improvement intervention effect in clinical setting, we will conduct a cluster-randomized clinical trial among China PUlmonary Thromboembolism REgistry Study (CURES) group, aiming to test whether it's applicable to real-world practice in China. A multicenter, two-arms, open-label clinical trial has been designed to determine whether the system-wide multifaceted intervention could increase the rate of at-risk participants who received prophylaxis (RP) and decrease the incidence of any hospital-associated VTE in 90 days during and after hospital admission. .Selected hospital will be regarded as a cluster and randomized into interventional or control group.In interventional group, eligible hospitalized patients will receive a variety of the multifaceted quality improvement(QI) interventions since admitted in hospital.In control group, patients will receive no more than common recommended care or an existing policy.The primary outcomes are the proportion of appropriate prophylaxis in hospitalized patients and the incidence of HA-VTE in 90 days after hospital admission.
Detailed Description
Hospitals nationwide which have willingness to participate this study in CURES group will be selected. Each selected hospital will be regarded as a cluster and randomized into interventional or control group. During the study period, eligible patients enrolled in hospitals assigned to interventional group will receive a variety of the multifaceted quality improvement(QI) interventions, including mandatory risk assessment, a computer alert(computer-based clinical decision support system and computerized reminders), strengthened education, and audit. Patients in hospitals assigned to control group will receive common recommended care only, or an existing policy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Thromboembolic Disease, Pulmonary Embolism, Venous Thromboembolism, Deep Venous Thrombosis, Quality Improvement
Keywords
Quality improvement, Venous Thromboembolism, Hospital Associated-VTE

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5800 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
The multifaceted QI interventions
Arm Type
Experimental
Arm Description
Hospitals randomized into experimental group will implement follow interventions including:the distribution of the guideline and pathway, a computer alert(computer-based clinical decision support system and computerized reminders),audit and feedback.
Arm Title
Routine VTE prophylaxis in local clinical practice
Arm Type
Active Comparator
Arm Description
Patients in the routine VTE prophylaxis(control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices.
Intervention Type
Other
Intervention Name(s)
The multifaceted interventions
Intervention Description
An evidence-based clinical guideline and pathway in hospital. A series Written care protocols for the implementation of performance measures. A computer-based clinical decision support system(CDSSs) and a computerized reminder, which was referred to as a key element to enhance VTE assessment and prophylaxis. A well-designed computer program will be integrated into the Electronic Medical Record(EMR) of intervention group and By processing, analyzing, summarizing and representing crucial information, physicians can be altered. A full-time quality coordinator A trained physician or nurse in each intervention cluster will be acted as a quality coordinator. The responsibility of the quality coordinator includes:
Intervention Type
Other
Intervention Name(s)
Routine VTE prophylaxis
Intervention Description
Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
Primary Outcome Measure Information:
Title
Proportion of appropriate prophylaxis rate during hospitalization
Description
The proportion of appropriate prophylaxis is defined as the number of appropriate prophylaxis among the patients at risk of VTE and without corresponding contraindications.
Time Frame
90 days after hospital admission
Title
The proportion of participants who developed the VTE(all, symptomatic, asymptomatic VTE)
Description
The incidence of HA-VTE is defined as the proportion of participants who developed the VTE(all, symptomatic, asymptomatic VTE)
Time Frame
90 days after hospital admission
Secondary Outcome Measure Information:
Title
All-cause mortality
Description
Proportion of participants who was dead(all-cause mortality)
Time Frame
90 days after hospital admission
Title
Proportion of complications related to the intervention
Description
complications(i.e. major bleeding,minor bleeding, thrombocytopenia) related to the intervention
Time Frame
90 days after hospital admission

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged ≥14 years Have an expected hospital stay ≥72 hours for medical and/or surgical treatment Written informed consent Exclusion Criteria: Inability to be followed-up at until 3 months after randomization Have participated in similar trials or are undergoing other clinical trials Refuse or are unable to give informed consent VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment Requiring a full dose of anticoagulant treatment (e.g., recent VTE, atrial fibrillation).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhenguo Zhai, Doctor
Phone
86-10-84206265
Email
zhaizhenguo2011@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhenguo Zhai, Doctor
Organizational Affiliation
China-Japan Friendship Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
China-Japan Friendship Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhenguo Zhai, M.D. Ph.D

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19364975
Citation
Piazza G, Rosenbaum EJ, Pendergast W, Jacobson JO, Pendleton RC, McLaren GD, Elliott CG, Stevens SM, Patton WF, Dabbagh O, Paterno MD, Catapane E, Li Z, Goldhaber SZ. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation. 2009 Apr 28;119(16):2196-201. doi: 10.1161/CIRCULATIONAHA.108.841197. Epub 2009 Apr 13. Erratum In: Circulation. 2010 Jul 6;122(1):e4.
Results Reference
background
PubMed Identifier
23279972
Citation
Pai M, Lloyd NS, Cheng J, Thabane L, Spencer FA, Cook DJ, Haynes RB, Schunemann HJ, Douketis JD. Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. Implement Sci. 2013 Jan 2;8:1. doi: 10.1186/1748-5908-8-1.
Results Reference
background
PubMed Identifier
15758007
Citation
Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005 Mar 10;352(10):969-77. doi: 10.1056/NEJMoa041533.
Results Reference
background
PubMed Identifier
27115264
Citation
Writing Group for the CHECKLIST-ICU Investigators and the Brazilian Research in Intensive Care Network (BRICNet); Cavalcanti AB, Bozza FA, Machado FR, Salluh JI, Campagnucci VP, Vendramim P, Guimaraes HP, Normilio-Silva K, Damiani LP, Romano E, Carrara F, Lubarino Diniz de Souza J, Silva AR, Ramos GV, Teixeira C, Brandao da Silva N, Chang CC, Angus DC, Berwanger O. Effect of a Quality Improvement Intervention With Daily Round Checklists, Goal Setting, and Clinician Prompting on Mortality of Critically Ill Patients: A Randomized Clinical Trial. JAMA. 2016 Apr 12;315(14):1480-90. doi: 10.1001/jama.2016.3463.
Results Reference
background
PubMed Identifier
19584716
Citation
Garcia DA, Highfill J, Finnerty K, Varoz E, McConkey S, Hutchinson K, Libby E. A prospective, controlled trial of a pharmacy-driven alert system to increase thromboprophylaxis rates in medical inpatients. Blood Coagul Fibrinolysis. 2009 Oct;20(7):541-5. doi: 10.1097/MBC.0b013e32832d6cfc.
Results Reference
background
PubMed Identifier
16961674
Citation
Fontaine A, Mahe I, Bergmann JF, Fiessinger JN, Dhote R, Cohen P, Vinceneux P. Effectiveness of written guidelines on the appropriateness of thromboprophylaxis prescriptions for medical patients: a prospective randomized study. J Intern Med. 2006 Oct;260(4):369-76. doi: 10.1111/j.1365-2796.2006.01699.x.
Results Reference
background
PubMed Identifier
32474204
Citation
Dong F, Zhen K, Zhang Z, Si C, Xia J, Zhang T, Xia L, Wang W, Jia C, Shan G, Zhai Z, Wang C; Chinese Prevention Strategy for Venous Thromboembolism (CHIPS-VTE) study group. Effect on thromboprophylaxis among hospitalized patients using a system-wide multifaceted quality improvement intervention: Rationale and design for a multicenter cluster randomized clinical trial in China. Am Heart J. 2020 Jul;225:44-54. doi: 10.1016/j.ahj.2020.04.020. Epub 2020 May 7.
Results Reference
derived

Learn more about this trial

CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism

We'll reach out to this number within 24 hrs